Pharma Journalist -

CrossBridge Bio, Inc., a pre-clinical biotech firm specializing in next-generation antibody-drug conjugates (ADCs), has agreed to be acquired by Eli Lilly and Company in a deal valued…
Read More...

As New Approach Methodologies (NAMs) and microphysiological systems (MPS) continue to gain momentum across drug development, the imperative facing industry scientists is increasingly…
Read More...

Replimune Group has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its Biologics License Application (BLA) seeking approval of RP1 in…
Read More...

Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to jointly develop and commercialize next-generation radiopharmaceutical therapies, marking…
Read More...

AbbVie has announced encouraging late-breaking results from its Phase 2 IMGN853-0420 clinical trial, showcasing the potential of mirvetuximab soravtansine-gynx in treating recurrent…
Read More...

Daiichi Sankyo and Merck & Co. (known as MSD outside the United States and Canada) have announced that the U.S. Food and Drug Administration has accepted and granted Priority Review…
Read More...

Novo Nordisk has announced a strategic partnership with OpenAI aimed at transforming healthcare through advanced artificial intelligence, with a focus on accelerating drug discovery and…
Read More...

As antibody-drug conjugates (ADCs) continue to move into more complex payload classes and higher drug–antibody ratios, linker and conjugation chemistry remains a critical bottleneck for…
Read More...

Telix Pharmaceuticals Limited has announced that the U.S. Food and Drug Administration has accepted its resubmitted New Drug Application (NDA) for TLX101-Px, an investigational imaging…
Read More...

C4 Therapeutics, Inc. has announced a new collaboration agreement with Roche to advance research in a promising cancer treatment approach known as degrader-antibody conjugates (DACs).…
Read More...